ArticleJournal of advanced research2026
Dexmedetomidine improves sleep quality and alleviates emotional dysfunction by attenuating α-synuclein deposition in mice with sepsis-associated encephalopathy.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Encephalopathy: Cause, Pathogenesis, and Treatment.MedComm · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMost septic patients have severe sleep disorders that are closely related to poor prognoses, and some patients with sepsis-associated encephalopathy (SAE) experience severe cerebral inflammatory reactions similar to those in neurodegenerative disease. α-synuclein, a widely expressed synaptic protein whose abnormal deposition can lead to neurodegenerative diseases, was also observed to be deposited abnormally in an SAE mouse model.
objectivesSleep disorders are common in SAE patients and are strongly associated with prognoses. Our aim is to clarify sleep architecture changes, investigate the link between sleep and α-synuclein deposition, and identify new target for SAE treatment.
methodsInjection of lipopolysaccharide i.cv and cecum ligation and puncture were used to establish SAE models. The telemetric implantation system was used to record electroencephalogram and electromyography signals of animals. Biological signal analysis, behavioral tests and molecular biology techniques were employed to investigate the relationship among sleep, α-synuclein, and emotional dysfunction of SAE mice. In addition, dexmedetomidine (50 ug kg
resultsSAE mice exhibited severe sleep fragmentation, including increased frequency of sleep and wakefulness, and decreased sleep quality. Fragmented sleep leading to α-synuclein deposition in the hippocampus, and developed anxiety and depression-like symptoms. Dexmedetomidine treatment not only improved sleep disorders but also reduced α-synuclein accumulation in the brain, thereby improving the mental symptoms associated with SAE.
conclusionWe have identified details related to poor sleep quality in sepsis, and these changes promote α-synuclein deposition in the brain and have a negative impact on the prognosis of SAE. Furthermore, dexmedetomidine confers the novel effect of facilitating α-synuclein elimination beyond its sedative effect. These findings highlight the pivotal role of sleep quality in pathological process of SAE, while suggesting that α-synuclein may serve as a promising therapeutic target for SAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.